SALT LAKE CITY, UT -- (MARKET WIRE) -- February 20, 2007 -- BSD Medical Corp. (AMEX: BSM) today announced that an article published in the Journal of the National Cancer Institute (see JNCI Vol. 99, No. 1, pp. 53-63) describes laboratory research at Duke University into the use of hyperthermia therapy to turn chemotherapy into a “smart weapon” for attacking cancer. Further, researchers at Duke University have now begun testing the use of encapsulated chemotherapy drug using a BSD Medical system to provide precision heat therapy (hyperthermia) in women whose breast cancers have recurred in their chest wall. The chemotherapy drug is packed into tiny heat-sensitive capsules. When the capsules are delivered by blood flow into a tumor, the tumor is heated, with the object of causing the capsule to release the chemotherapy into the tumor without subjecting the rest of the body to the toxicity of chemotherapy. When chemotherapy drugs are injected into the blood stream they circulate through the body with the hope that they will be able to penetrate and effectively attack cancerous tumors where they find them. The focus of this research is to target anti-cancer activity of conventional weapons against cancer, like chemotherapy, directly at the tumor, with the objective of decreasing the high percentage of cancer patients who continue to die from cancer despite conventional therapy.
